Literature DB >> 20971076

Role of lymphocyte-specific protein tyrosine kinase (LCK) in the expansion of glioma-initiating cells by fractionated radiation.

Rae-Kwon Kim1, Chang-Hwan Yoon, Kyung-Hwan Hyun, Hyejin Lee, Sungkwan An, Myung-Jin Park, Min-Jung Kim, Su-Jae Lee.   

Abstract

Brain cancers frequently recur or progress as focal masses after treatment with ionizing radiation. Radiation used to target gliomas may expand the cancer stem cell population and enhance the aggressiveness of tumors; however, the mechanisms underlying the expansion of cancer stem cell population after radiation have remained unclear. In this study, we show that LCK (lymphocyte-specific protein tyrosine kinase) is involved in the fractionated radiation-induced expansion of the glioma-initiating cell population and acquisition of resistance to anticancer treatments. Fractionated radiation caused a selective increase in the activity of LCK, a Src family non-receptor tyrosine kinase. The activities of other Src family kinases Src, Fyn, and Lyn were not significantly increased. Moreover, knockdown of LCK expression with a specific small interfering RNA (siRNA) effectively blocked fractionated radiation-induced expansion of the CD133(+) cell population. siRNA targeting of LCK also suppressed fractionated radiation-induced expression of the glioma stem cell marker proteins CD133, Nestin, and Musashi. Expression of the known self-renewal-related proteins Notch2 and Sox2 in glioma cells treated with fractionated radiation was also downregulated by LCK inhibition. Moreover, siRNA-mediated knockdown of LCK effectively restored the sensitivity of glioma cells to cisplatin and etoposide. These results indicate that the non-receptor tyrosine kinase LCK is critically involved in fractionated radiation-induced expansion of the glioma-initiating cell population and decreased cellular sensitivity to anticancer treatments. These findings may provide pivotal insights in the context of fractionated radiation-based therapeutic interventions in brain cancer.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971076     DOI: 10.1016/j.bbrc.2010.10.072

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y.

Authors:  Ulrike Olszewski; Anthony Deally; Matthias Tacke; Gerhard Hamilton
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

2.  A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype.

Authors:  E Gangoso; C Thirant; H Chneiweiss; J M Medina; A Tabernero
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

3.  New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.

Authors:  Ahmed Elkamhawy; Eslam M H Ali; Kyeong Lee
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

4.  Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation.

Authors:  Shahrooz Vahedi; Fu-Yu Chueh; Bala Chandran; Chao-Lan Yu
Journal:  BMC Cancer       Date:  2015-07-26       Impact factor: 4.430

5.  The role of Src family kinases in growth and migration of glioma stem cells.

Authors:  Xiaosi Han; Wenbin Zhang; Xiuhua Yang; Crystal G Wheeler; Catherine P Langford; Lu Wu; Natalia Filippova; Gregory K Friedman; Qiang Ding; Hassan M Fathallah-Shaykh; G Yancey Gillespie; L Burt Nabors
Journal:  Int J Oncol       Date:  2014-05-09       Impact factor: 5.650

6.  Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells.

Authors:  Alessandro Corsaro; Adriana Bajetto; Stefano Thellung; Giulia Begani; Valentina Villa; Mario Nizzari; Alessandra Pattarozzi; Agnese Solari; Monica Gatti; Aldo Pagano; Roberto Würth; Antonio Daga; Federica Barbieri; Tullio Florio
Journal:  Oncotarget       Date:  2016-06-21

7.  Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor.

Authors:  J P Zepecki; K M Snyder; M M Moreno; E Fajardo; A Fiser; J Ness; A Sarkar; S A Toms; N Tapinos
Journal:  Oncogene       Date:  2018-10-23       Impact factor: 9.867

8.  LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme.

Authors:  Le Ge; Lixia Xu; Shan Lu; Hua Yan
Journal:  FEBS Open Bio       Date:  2020-04-13       Impact factor: 2.693

9.  A comprehensive analysis of the expression and regulation network of lymphocyte-specific protein tyrosine kinase in breast cancer.

Authors:  Yuhua Meng; Ting Huang; Xuanzhao Chen; Yuanzhi Lu
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.